Cheng, Ying http://orcid.org/0000-0001-9908-597X
Wang, Qiming
Li, Kai
Shi, Jianhua
Liu, Ying
Wu, Lin
Han, Baohui
Chen, Gongyan
He, Jianxing
Wang, Jie
Lou, Donghua
Yu, Hao
Wang, Shanchun
Qin, Haifeng
Li, Xiaoling
Funding for this research was provided by:
Chia-tai Tianqing Pharmaceutical Group Co., Ltd.
Article History
Received: 23 August 2020
Revised: 19 February 2021
Accepted: 11 March 2021
First Online: 18 May 2021
Ethics approval and consent to participate
: The study was performed in accordance with the Declaration of Helsinki and Guidelines for Good Clinical Practice, as well as laws and regulations in China. The study protocol was approved by the institutional review board in each participating institution. All patients provided written informed consent before any study-related procedure.
: The data used and analysed during the current study are available from the corresponding author on reasonable request.
: S.W. is a senior engineer of Chia-tai Tianqing Pharmaceutical Group Co., Ltd. All the other authors declare no conflict of interests.
: This work was supported by Chia-tai Tianqing Pharmaceutical Group Co., Ltd. The funder had no role in the design the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication. The funder provided the study drug. This paper is supported by the Special Project for Significant New Drug Research and Development in the Major National Science and Technology Projects of China (project no. 2020ZX09201-024).